Specifically, CAR-T cells targeting Tn-MUC1 developed by Posey et al. were advanced to a clinical trial with patients with Tn-MUC1-overexpressing cancers, including pancreatic cancer and triple-negative breast cancer, and no significant safety concerns or on-target/off-tumor toxicity were reported (NCT04025216)23,32. This evidence concerns the gene MUC1 and cancer.